# Reverse Medical

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/reverse-medical

- Industry: Medical Devices & Equipment
- Headquarters: Irvine, US
- Website: www.reversemed.com
- Total disclosed funding: $14M
- Latest round: Series B (Mar 30, 2010)
- Investors on record: 8

## About

Reverse Medical Corp. is a medical device company focused on developing innovative vascular intervention solutions for the treatment of aneurysms and other vascular conditions.Reverse Medical Corporation, founded in 2007 and headquartered in Irvine, US, specializes in vascular intervention technologies. The company was acquired by Covidien in August 2014 for an undisclosed amount. Throughout its operation, Reverse Medical has successfully completed three deals, with its most recent deal occurring in 2014.Reverse Medical Corp. is dedicated to creating advanced medical devices that focus on vascular interventions. Their primary offerings include innovative solutions for aneurysm treatment and other vascular conditions, which aim to enhance patient outcomes through effective management and treatment options. The company supplies its products to hospitals and healthcare providers across multiple regions, including North America, Europe, and Asia-Pacific.Reverse Medical Corp. generates revenue from the sales of its specialized vascular devices and solutions to healthcare institutions. The company operates on a B2B basis, engaging in direct sales to hospitals, often involving bulk purchases accompanied by maintenance and support services, ensuring a steady revenue generation as healthcare providers adopt their advanced technologies into patient care.Looking ahead, Reverse Medical Corp. aims to expand its product portfolio with the development of new vascular intervention solutions. While specific release dates are not mentioned, the company is actively working on enhancing its offerings. Additionally, Reverse Medical plans to extend its market reach into new geographic regions, targeting Europe and Asia by 2025. The recent Series B funding round, which raised USD 14.00 mn, will be utilized to support these growth initiatives and further product development.

## Funding rounds

- Series B, Mar 30, 2010, $14M — Wexford Capital, BioStar Capital, Stage Capital, Early Stage Partners, Emergent Medical Ventures, Getz Bros., MedFocus Funds, South Australian Life Science Advancement Partnership

## Investors

- Wexford Capital — Series B
- BioStar Capital (https://capitalatlas.ai/funds/biostar-capital) — Series B
- Stage Capital (https://capitalatlas.ai/funds/stage-capital) — Series B
- Early Stage Partners (https://capitalatlas.ai/funds/early-stage-partners) — Series B
- Emergent Medical Ventures (https://capitalatlas.ai/funds/emergent-medical-ventures) — Series B
- Getz Bros. — Series B
- MedFocus Funds (https://capitalatlas.ai/funds/medfocus-funds) — Series B
- South Australian Life Science Advancement Partnership — Series B